ECM
MESO

Evergreen Capital Management’s Mesoblast MESO Stock Holding History

Evergreen Capital Management’s Portfolio MESO Stock Details MESO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,006
Closed -$62.6K – 829
2023
Q2 		$62.6K Buy
+8,006
New +$57.2K ﹤0.01% 792

Other funds holding MESO

PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
LCM
Lazari Capital Management Woodland Hills, California $287M AUM 28.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
PWM
Prosperity Wealth Management San Ramon, California $300M AUM 28.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Evergreen Capital Management's MESO Position: Q3 2023 in Review

Evergreen Capital Management sold out of Mesoblast (MESO) in Q3 2023, closing a stake of 8,006 shares — an estimated $62.6K sold.

Evergreen Capital Management first reported a position in MESO in Q2 2023 and held it in 1 quarter. The position peaked at $62.6K in Q2 2023. 35 funds tracked by Wall St. Rank hold MESO as of Q3 2023.

  • Evergreen Capital Management reported no remaining Mesoblast position as of Q3 2023 after selling out during the quarter.
  • Evergreen Capital Management sold 8,006 Mesoblast shares in Q3 2023, an estimated $62.6K.
  • Evergreen Capital Management first reported a position in Mesoblast in Q2 2023 and held it in 1 quarter.
  • Evergreen Capital Management's Mesoblast position peaked at $62.6K in Q2 2023.
  • 35 funds tracked by Wall St. Rank held Mesoblast as of Q3 2023.

Based on Evergreen Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.